Home > News > Introgen applies to market Advexin in Europe
November 13th, 2007
Introgen applies to market Advexin in Europe
Abstract:
Introgen Therapeutics Inc. and its subsidiary, Gendux Molecular Ltd., have submitted a marketing authorization application to the European Medicines Agency for Advexin, a tumor suppressor therapy for use in the treatment of a type of cancer known as Li-Fraumeni Syndrome.
Austin-based Introgen (NASDAQ: INGN) has offices housing a clinical and regulatory development staff of about 70 in the Texas Medical Center plus a manufacturing facility nearby.
A year ago, the biotech company obtained an exclusive worldwide license to a portfolio of patents from The University of Texas M.D. Anderson Cancer Center, along with agreements to commercialize products based on the licensed technologies. Those patents are focused on the delivery of biologically active proteins, polypeptides and peptides on the nanoparticle level.
Source:
bizjournals.com
Bookmark:
| Related News Press |
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Rice membrane extracts lithium from brines with greater speed, less waste October 3rd, 2025
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||